Form 4: EXAS Exec's Stock Vesting & Tax Withholding

Exact Sciences EVP Jacob Orville reported the vesting of restricted stock units and subsequent tax-related share withholding.

Summary

• Jacob A. Orville, Executive Vice President and General Manager of Screening at Exact Sciences Corp (EXAS), acquired 5,350 shares of common stock on August 5, 2025, through the vesting of restricted stock units.
• Concurrently, 2,515 shares were disposed of at a price of $46.83 per share to cover tax withholding obligations associated with the RSU vesting.
• Following these transactions, Orville directly holds 28,237 shares of common stock and indirectly holds an additional 1,490 shares in a 401(k) Plan, totaling 29,727 shares.
• Orville also maintains an aggregate of 79,661 vested and unvested options to purchase common stock and additional restricted stock units.
• The restricted stock unit award that partially vested on August 5, 2025, was originally granted on August 5, 2024, and is structured to vest in four equal annual installments.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive. It reflects routine executive compensation and tax management, indicating stability in executive retention. No negative operational or financial news is present.

Positives

• The vesting of restricted stock units represents a routine component of executive compensation, indicating the retention and alignment of a key executive, Jacob A. Orville, with the company's long-term performance.
• The executive's continued significant equity holdings, including vested and unvested options and restricted stock units, reinforce an alignment of interests with shareholders.

Negatives

• A portion of the vested shares was sold to cover tax obligations, which is a standard practice but results in a reduction of the executive's direct share ownership.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook. It solely reports an insider's equity transactions.

Industry Context

This Form 4 filing is a routine disclosure of an executive's equity compensation and tax-related transactions. It does not provide information relevant to broader industry trends or competitive dynamics within the diagnostics or healthcare sector.

Comparison to Industry Standards

• This filing details an executive's compensation-related stock transactions, which are standard practice across industries.
• It does not contain information that allows for a direct comparison of company performance or specific projects against global benchmarks or comparable companies.

Stakeholder Impact

• Shareholders: The vesting and tax-related sale are routine and reflect executive compensation, aligning executive interests with shareholder value through equity ownership.
• Employees: No direct impact on general employees.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Future annual installments of the restricted stock unit award are expected to vest as per the original grant terms.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, specifically the vesting of restricted stock units and subsequent tax-related share withholding. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The executive's continued significant equity holdings suggest alignment with shareholder interests, supporting a 'hold' stance based solely on this filing.

Keywords

Exact Sciences, EXAS, Insider Transaction, Form 4, Restricted Stock Units, Executive Compensation, Stock Vesting, Jacob Orville